Skip to main content

AAPS

Events
  • Live Events
  • On Demand Events
Courses
Product Bundles
aaps.org
Search
Cart 0
Sign Up
Sign In

Item Added to Cart

You just added

You have item(s) in your cart

  • Proceed to Checkout

Colonic Drug Absorption- Part 2: Developing Colon-targeting Formulations

  • Overview

Thank you

This live web event has ended. Thank you for attending.

Description

The oral absorption process consists of numerous hurdles that a drug needs to conquer before reaching systemic circulation. Drug release and absorption are quite complex considering the dynamic nature of the human gastrointestinal (GI) tract. Depending on (i) the desired systemic exposure and (ii) the associated pharmacodynamic effect, drug release can be triggered across the human GI tract as such to deliver the drug in a specific region at a specific release rate. In the particular interest of locally-acting drugs, numerous drug delivery strategies are developed to target drug release in assigned regions of the colon especially when interested in the treatment of inflammatory bowel diseases (e.g., ulcerative colitis). Reaching the most distal parts of the human GI tract is challenging as extra barriers need to be conquered compared to oral drug delivery in the more proximal parts. In the following series of webinars as organized by the Oral Biopharmaceutics and Modeling (OBAM) community of AAPS, an in-depth overview of (i) physiological aspects of the colonic environment, (ii) colonic-targeted formulations and (iii) predictions towards colonic absorption will be thoroughly discussed.

Part 2: Developing Colon-targeting Formulations
There are two major reasons for developing colon-targeting formulations. The first is to create extended-release formulations for rapidly absorbed immediate-release products in order to limit number of daily doses to one or two. Such products typically rely on their good colonic absorption. The second is the targeted release of drugs in colon for the treatment of colonic diseases, in which case the absorption from the colon might not be desired. This webinar will be focus on formulation design and strategies in pursuit of colonic release.

Learning Objectives:

  • Which physico-chemical properties of the drug determine its potential for colonic absorption.
  • Type of colon-targeting formulations.
  • Formulation strategies to overcome the hurdles associated with colonic delivery – low fluid content, residual bile salts, high pH, etc.

Contributors

  • Filippos Kesisoglou, Ph.D.

    Filippos Kesisoglou is a Distinguished Scientist at Merck & Co., Inc., (Rahway, NJ) where he is currently leading the Biopharmaceutics efforts in the Pharmaceutical Sciences department. Filippos has more than 15 years of experience in the fields of biopharmaceutics and formulation development, pharmacokinetics, PBPK and IVIVC modeling as related to clinical, drug product development and CMC regulatory applications across modalities. He has been a key contributor to several new drug applications. He has authored/co-authored 90 manuscripts/book chapters and more than 80 conference abstracts/podium presentations in several national/international meetings in the fields of biopharmaceutics, PBPK modeling, formulation development and drug delivery. Filippos has been an active member of AAPS and has been involved over the years in several cross-industry and academia consortia. He is currently serving as an Editor for Journal of Pharmaceutical Sciences and on the Editorial Advisory Board for the AAPS Journal and Pharmaceutical Research. In 2017 he was elected a Fellow of the American Association of Pharmaceutical Scientists (AAPS).

  • Joseph Della Rocca, Ph.D.

    Joseph Della Rocca is an associate principal scientist in the Oral Formulation Sciences group at Merck. Joseph started his career at Merck in Discovery Pharmaceutical Sciences, focusing on formulation and analytical support for discovery programs. In 2018, Joseph joined the oral formulation sciences group, supporting formulation design and process development across development. Joseph’s current focus is on the development of controlled release dosage forms.

April 20, 2023
Thu 12:30 PM EDT

Duration 1H 0M

This live web event has ended.

For Technical Support
support@blueskyelearn.com
+1 (858) 201-4136
Register
Log In
  • New
  • Existing

Forgot password?
  • Events
  • Courses
  • Search
  • Support
  • eCourse FAQs
  • Sign Up
  • Sign In
  • Privacy Policy | Cookies Policy